Edition:
United States

Novartis AG (NVS.N)

NVS.N on New York Stock Exchange

74.37USD
24 Mar 2017
Change (% chg)

$-0.06 (-0.08%)
Prev Close
$74.43
Open
$74.26
Day's High
$74.49
Day's Low
$74.08
Volume
455,352
Avg. Vol
641,322
52-wk High
$83.58
52-wk Low
$66.93

Latest Key Developments (Source: Significant Developments)

Shares in pharma company Genfit surge for second day in row
Tuesday, 14 Mar 2017 04:16am EDT 

Genfit : Shares up around 5 pct, building on 13.4 percent gain on March 13 . Genfit, which specializes in the development of medicines for the prevention and treatment of diabetes and related disorders, has declined to comment on reports that it is a takeover target [nL5N1GQ5PZ] . Previous reports have mentioned Novartis as being interested in buying Genfit [nL5N1GF5CA] Further company coverage: [GNFT.PA] ((sudip.kargupta@thomsonreuters.com;)).  Full Article

Novartis Chairman: No decision yet on Alcon's future
Tuesday, 28 Feb 2017 06:13am EST 

Novartis Ag : Chairman Joerg Reinhardt told shareholders at the Swiss drugmaker's annual general meeting that he sees Google lens project as "high risk project" . He does not expect "path breaking" success for Google project within 3-4 years .Chairman says no decision yet on Alcon future, but remains confident in improving performance this year at eye-care division.  Full Article

Novartis says Zykadia drug receives FDA priority review
Thursday, 23 Feb 2017 07:30am EST 

Novartis AG : Novartis drug Zykadia receives FDA priority review for first-line use in patients with ALK+ metastatic NSCLC .Novartis AG - FDA also granted breakthrough therapy designation to Zykadia.  Full Article

Novartis says Zykadia drug gets FDA priority review
Thursday, 23 Feb 2017 01:18am EST 

Novartis AG : Novartis drug zykadia receives fda priority review for first-line use in patients with alk+ metastatic nsclc . Says novartis drug zykadia receives fda priority review for first-line use in patients with alk+ metastatic nsclc .Says fda also grants breakthrough therapy designation based on phase iii data in previously untreated alk+ metastatic nsclc patients with metastases to brain.  Full Article

Incyte reports Q4 earnings per share $0.05
Tuesday, 14 Feb 2017 07:00am EST 

Incyte Corp : Incyte reports 2016 fourth-quarter and year-end financial results, provides 2017 financial guidance and updates on key clinical programs . Q4 revenue $326 million versus I/B/E/S view $324.4 million . Q4 earnings per share $0.05 . Q4 earnings per share view $0.13 -- Thomson Reuters I/B/E/S . Sees 2017 Jakafi net product revenues $1,020-$1,070 million . Sees 2017 ongoing research and development expenses $785-$835 million . Sees 2017 change in fair value of acquisition-related contingent consideration $30-$35 million . Incyte Corp - pivotal program of ruxolitinib as a treatment for patients with essential thrombocythemia is also expected to begin in 2017 .Incyte - phase 3 trials in steroid-refractory acute, steroid-refractory chronic gvhd, respectively, expected to begin in 2017 with novartis.  Full Article

Novartis says Alcon launches new lens for astigmatism
Thursday, 26 Jan 2017 01:00am EST 

Novartis : Says Alcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgery Further company coverage: [NOVN.S] (Reporting By Zurich newsroom) ((zurich.newsroom@thomsonreuters.com; +41 58 306 7336;)).  Full Article

Novartis expects CART therapy CTL019 to exceed $1 bln in annual sales
Wednesday, 25 Jan 2017 08:50am EST 

Novartis : Says elevates cart therapy ctl019 to group of drugs it expects will be blockbusters, with at least $1 billion in annual sales . Says diffuse large b-cell lymphoma indication likely to propel ctl019 to blockbuster status, filing expected in 2017 depending on data .still plans initial q2 2017 regulatory filing in United States for CTL019 in in relapsed/refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia.  Full Article

Novartis's Alcon head expects op. profit to hit trough in 2017
Wednesday, 25 Jan 2017 08:36am EST 

Novartis Ag : Alcon unit head says fixing supply, service issues 'more challenging than originally imagined' . Ceo says has not ruled out sale of alcon to strategic buyer .Alcon head expects operating profit to reach trough in 2017.  Full Article

Novartis CEO plans to meet with US President Trump, no date set
Wednesday, 25 Jan 2017 07:06am EST 

Novartis Ag : Says expects to grow in each year in 2018, 2019 and 2020 . Cfo says plans to finance $5 billion share buyback with debt . Ceo says goodwill, intangibles of alcon is $16.9 billion, does not anticipate loss after impairment testing . Ceo won't speculate on prequisites for keeping alcon, 'we're going to make a decision" based on how alcon progresses . Ceo says has outcomes based pricing contracts for gilenya, tasigna following entresto deals .Ceo says plans to meet with president trump, "love to in coming months sit down with administration" to consult on affordable care; no meeting set yet.  Full Article

Alcon receives U.S. FDA approval for acrysof® iq restor® +3.0d multifocal toric intraocular lens
Thursday, 22 Dec 2016 06:00pm EST 

Novartis Ag : Alcon - U.S. commercialization expected to start on a rolling basis in Q1 of 2017 for acrysof iq restor .Alcon receives U.S. FDA approval for acrysof® iq restor® +3.0d multifocal toric intraocular lens for cataract patients.  Full Article

More From Around the Web

Photo

Novartis heart drug portfolio hit by failed serelaxin study

ZURICH Novartis's heart failure drug serelaxin flopped in a late-stage trial by not cutting cardiovascular death or slowing disease progression, marking the likely demise of a drug hopeful the Swiss firm had promoted as a potential blockbuster.